explore -WSS

explore

author：focus 2025-10-01 14:15:37 - browse：4983

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： STAT Summit: How researchers deal with rejection

focus

WSS

Campaign finance charge dropped from case against Sam Bankman

Roche drug slashes death risk in early

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

What AstraZeneca

HCA says smaller share of spending going to labor

Wikipedia

explore

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Is there really a nursing shortage in the U.S.?

United colonoscopy coverage change 'may cost lives,' doctors say

ADCs take center stage as promising cancer treatments

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

How one medical school became remarkably diverse

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

entertainment

Doctors in states that ban abortion can still help patients

J&J lung cancer data amount to new salvo against AstraZeneca

Europe is fastest

'Weather

Readout LOUD podcast: Live from the 2023 STAT Summit

Cassava Sciences’ Alzheimer’s clinical trials should be halted

knowledge

focus

explore

hotspot